BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 29661116)

  • 1. CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells.
    Ouyang S; Xie Y; Xiong Z; Yang Y; Xian Y; Ou Z; Song B; Chen Y; Xie Y; Li H; Sun X
    Stem Cells Dev; 2018 Jun; 27(11):756-770. PubMed ID: 29661116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cells.
    He L; Wang S; Peng L; Zhao H; Li S; Han X; Habimana JD; Chen Z; Wang C; Peng Y; Peng H; Xie Y; Lei L; Deng Q; Wan L; Wan N; Yuan H; Gong Y; Zou G; Li Z; Tang B; Jiang H
    Transl Psychiatry; 2021 Sep; 11(1):479. PubMed ID: 34535635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy Promoted the Degradation of Mutant ATXN3 in Neurally Differentiated Spinocerebellar Ataxia-3 Human Induced Pluripotent Stem Cells.
    Ou Z; Luo M; Niu X; Chen Y; Xie Y; He W; Song B; Xian Y; Fan D; OuYang S; Sun X
    Biomed Res Int; 2016; 2016():6701793. PubMed ID: 27847820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAN Translation of the Expanded CAG Repeats in the SCA3 Disease Context.
    Jazurek-Ciesiolka M; Ciesiolka A; Komur AA; Urbanek-Trzeciak MO; Krzyzosiak WJ; Fiszer A
    J Mol Biol; 2020 Dec; 432(24):166699. PubMed ID: 33157084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of an induced pluripotent stem cell line from a patient with spinocerebellar ataxia type 3 (SCA3): HIHCNi002-A.
    Hayer SN; Schelling Y; Huebener-Schmid J; Weber JJ; Hauser S; Schöls L
    Stem Cell Res; 2018 Jul; 30():171-174. PubMed ID: 29936336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of induced pluripotent stem cells from a patient with spinocerebellar ataxia type 3.
    Soong BW; Syu SH; Wen CH; Ko HW; Wu ML; Hsieh PC; Hwang SM; Lu HE
    Stem Cell Res; 2017 Jan; 18():29-32. PubMed ID: 28395798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
    Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC
    Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induced pluripotent stem cell - derived neurons for the study of spinocerebellar ataxia type 3.
    Hansen SK; Stummann TC; Borland H; Hasholt LF; Tümer Z; Nielsen JE; Rasmussen MA; Nielsen TT; Daechsel JC; Fog K; Hyttel P
    Stem Cell Res; 2016 Sep; 17(2):306-317. PubMed ID: 27596958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of miR-25 and miR-181 Family Members Correlates with Reduced Expression of ATXN3 in Lymphocytes from SCA3 Patients.
    Krauss S; Nalavade R; Weber S; Carter K; Evert BO
    Microrna; 2019; 8(1):76-85. PubMed ID: 30147021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of induced pluripotent stem cell line (ZZUi0014-A) from a patient with spinocerebellar ataxia type 3.
    Wang Y; Sun H; Wang Z; Yue Y; Zhang R; Yang J; Liu Y; Liu H; Zhang Q; Zhang S; Zhang J; Xu Y; Shi C
    Stem Cell Res; 2019 Dec; 41():101564. PubMed ID: 31639609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3.
    Gao R; Liu Y; Silva-Fernandes A; Fang X; Paulucci-Holthauzen A; Chatterjee A; Zhang HL; Matsuura T; Choudhary S; Ashizawa T; Koeppen AH; Maciel P; Hazra TK; Sarkar PS
    PLoS Genet; 2015 Jan; 11(1):e1004834. PubMed ID: 25590633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deficiency in classical nonhomologous end-joining-mediated repair of transcribed genes is linked to SCA3 pathogenesis.
    Chakraborty A; Tapryal N; Venkova T; Mitra J; Vasquez V; Sarker AH; Duarte-Silva S; Huai W; Ashizawa T; Ghosh G; Maciel P; Sarkar PS; Hegde ML; Chen X; Hazra TK
    Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8154-8165. PubMed ID: 32205441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
    Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
    Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of human-induced pluripotent stem cell GZHMCi0011-A from peripheral blood mononuclear cells from a volunteer with 14/63 CAG repeats of the ATXN3 mutation.
    Hongmei G; Xiaofang S; Bing S
    Stem Cell Res; 2023 Oct; 72():103190. PubMed ID: 37866221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cell line SCA3.B11.
    Hansen SK; Borland H; Hasholt LF; Tümer Z; Nielsen JE; Rasmussen MA; Nielsen TT; Stummann TC; Fog K; Hyttel P
    Stem Cell Res; 2016 May; 16(3):589-92. PubMed ID: 27346191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cell line SCA3.A11.
    Hansen SK; Borland H; Hasholt LF; Tümer Z; Nielsen JE; Rasmussen MA; Nielsen TT; Stummann TC; Fog K; Hyttel P
    Stem Cell Res; 2016 May; 16(3):553-6. PubMed ID: 27346190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene editing as a therapeutic strategy for spinocerebellar ataxia type-3.
    Déglon N
    Rev Neurol (Paris); 2024 May; 180(5):378-382. PubMed ID: 38580500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3.
    Chen ZS; Huang X; Talbot K; Chan HYE
    Cell Death Dis; 2021 Feb; 12(2):136. PubMed ID: 33542212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urine levels of the polyglutamine ataxin-3 protein are elevated in patients with spinocerebellar ataxia type 3.
    Koike Y; Jansen-West KR; Hanna Al-Shaikh R; Carlomagno Y; Song Y; Dunmore JA; LeDoux MS; Friedman JH; Pena AB; Uitti RJ; Zaremba J; van Gerpen JA; Pfeiffer RF; Veerappan V; Aiba I; Hashimoto R; Giles SS; Shah JS; Tipton PW; Huang JF; Wierenga KJ; Aasly J; Fryer JD; Petrucelli L; Wszolek ZK; Prudencio M
    Parkinsonism Relat Disord; 2021 Aug; 89():151-154. PubMed ID: 34303201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.